Literature DB >> 7120720

Adrenoleukodystrophy: effects of dietary restriction of very long chain fatty acids and of administration of carnitine and clofibrate on clinical status and plasma fatty acids.

F R Brown, M A Van Duyn, A B Moser, J D Schulman, W B Rizzo, R D Snyder, J V Murphy, S Kamoshita, C J Migeon, H W Moser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7120720

Source DB:  PubMed          Journal:  Johns Hopkins Med J        ISSN： 0021-7263


× No keyword cloud information.
  17 in total

1.  Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil".

Authors:  B M van Geel; J Assies; E B Haverkort; J H Koelman; B Verbeeten; R J Wanders; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

Review 2.  X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy.

Authors:  B M van Geel; J Assies; R J Wanders; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

Review 3.  Evaluation of therapy of X-linked adrenoleukodystrophy.

Authors:  Hugo W Moser; Ali Fatemi; Kathleen Zackowski; Seth Smith; Xavier Golay; Larry Muenz; Gerald Raymond
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

Review 4.  Peroxisome biogenesis disorders in the Zellweger spectrum: An overview of current diagnosis, clinical manifestations, and treatment guidelines.

Authors:  Nancy E Braverman; Gerald V Raymond; William B Rizzo; Ann B Moser; Mark E Wilkinson; Edwin M Stone; Steven J Steinberg; Michael F Wangler; Eric T Rush; Joseph G Hacia; Mousumi Bose
Journal:  Mol Genet Metab       Date:  2015-12-23       Impact factor: 4.797

Review 5.  Fatty Acid Oxidation in Peroxisomes: Enzymology, Metabolic Crosstalk with Other Organelles and Peroxisomal Disorders.

Authors:  Ronald J A Wanders; Frédéric M Vaz; Hans R Waterham; Sacha Ferdinandusse
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

6.  Decreasing serum VLCFA levels in ageing X-ALD female carriers.

Authors:  T J Stradomska; A Tylki-Szymańska
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

7.  Brain, liver, and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceryl trierucate and trioleate oils (Lorenzo's oil).

Authors:  M Rasmussen; A B Moser; J Borel; S Khangoora; H W Moser
Journal:  Neurochem Res       Date:  1994-08       Impact factor: 3.996

8.  Thrombocytopenia induced by erucic acid therapy in patients with X-linked adrenoleukodystrophy.

Authors:  S Zierz; R Schröder; C J Unkrig
Journal:  Clin Investig       Date:  1993-10

Review 9.  Adrenoleukodystrophy: phenotypic variability and implications for therapy.

Authors:  H W Moser; A B Moser; K D Smith; A Bergin; J Borel; J Shankroff; O C Stine; C Merette; J Ott; W Krivit
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

10.  Glyceroltrioleate/glyceroltrierucate therapy in 16 patients with X-chromosomal adrenoleukodystrophy/adrenomyeloneuropathy: effect on clinical, biochemical and neurophysiological parameters.

Authors:  G C Korenke; D H Hunneman; J Kohler; S Stöckler; K Landmark; F Hanefeld
Journal:  Eur J Pediatr       Date:  1995-01       Impact factor: 3.183
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.